Logo
x

Search category

Subscribe Now

Amylyx

Amylyx Reports the Completion of Patient Enrollment in P-III Trial (PHOENIX) of AMX0035 for Amyotrophic Lateral Sclerosis

Amylyx Reports the Completion of Patient Enrollment in P-III Trial (PHOENIX) of AMX0035 for Amyotrophic Lateral Sclerosis

  • February 3, 2023
Amylyx’s Relyvrio (sodium phenylbutyrate and taurursodiol) Receives the US FDA’s Approval for the Treatment of ALS

Amylyx’s Relyvrio (sodium phenylbutyrate and taurursodiol) Receives the US FDA’s Approval for the Treatment of ALS

  • September 30, 2022
Amylyx Publishes Results of AMX0035 in P-II (CENTAUR) Trial for the Treatment of Amyotrophic Lateral Sclerosis in Muscle & Nerve

Amylyx Publishes Results of AMX0035 in P-II (CENTAUR) Trial for the Treatment of Amyotrophic Lateral Sclerosis in Muscle & Nerve

  • May 6, 2022
Amylyx Reports Submission of MAA to EMA for AMX0035 to Treat ALS

Amylyx Reports Submission of MAA to EMA for AMX0035 to Treat ALS

  • January 5, 2022
Amylyx Reports US FDA Acceptance of NDA and Priority Review for AMX0035 to Treat ALS

Amylyx Reports US FDA Acceptance of NDA and Priority Review for AMX0035 to Treat ALS

  • December 30, 2021
PharmaShots Weekly Snapshots (November 01, 03, 2021)

PharmaShots Weekly Snapshots (November 01, 03, 2021)

  • November 5, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.